0.280
0.13 (85.43%)
| Previous Close | 0.151 |
| Open | 0.151 |
| Volume | 23,778 |
| Avg. Volume (3M) | 3,218 |
| Market Cap | 583,100,736 |
| Price / Earnings (Forward) | 6.73 |
| Price / Sales | 4.63 |
| Price / Book | 4.31 |
| 52 Weeks Range | |
| Earnings Date | 28 Aug 2025 |
| Operating Margin (TTM) | -57,123.49% |
| Diluted EPS (TTM) | -2.25 |
| Quarterly Revenue Growth (YOY) | -26.20% |
| Current Ratio (MRQ) | 1.57 |
| Operating Cash Flow (TTM) | -157.81 M |
| Levered Free Cash Flow (TTM) | -79.30 M |
| Return on Assets (TTM) | -73.34% |
| Return on Equity (TTM) | -3,383.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Opthea Limited | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Relative Valuation | NA |
| Financial Health | -3.2 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.02 |
Select this tab to load the latest available analysis.
|
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Institutions | 5.06% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |